Media

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac

Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress

CurifyLabs Raises $14M Series A to Power the Future of Personalized Medicine

Vicore Pharma Appoints Rob Slack as Chief Scientific Officer

Vicore Pharma to Commence Trading in the United States on The Nasdaq Stock Market

Health is Wealth – Call for action – European Life Sciences Coalition open letter

Fortifying the Future of FSHD Research: AMRA Medical Heads to 33rd International Research Congress on FSHD